Emcure Pharmaceuticals announces the successful conclusion of a US FDA inspection at its manufacturing facility located in Kadu, Surendranagar, Gujarat. The inspection took place from October 6, 2025, to October 10, 2025. The company confirms that the inspection was concluded without any observations.
Successful FDA Inspection
Emcure Pharmaceuticals has completed a United States Food and Drug Administration (US FDA) surveillance inspection at its manufacturing facility in Kadu, Surendranagar, Gujarat. The inspection concluded on October 10, 2025.
Inspection Details
The US FDA conducted a surveillance inspection of the company’s manufacturing facility located at Survey No. 485 (New), 160/P1 (Old), Kadu, Taluka – Lakhtar, District- Surendranagar, Gujarat – 382775. The inspection commenced on October 6, 2025 and ended on October 10, 2025.
No Observations Noted
The company is pleased to announce that the inspection was concluded without any observations. This signifies Emcure’s commitment to maintaining high standards of quality and compliance at its manufacturing facilities.
Source: BSE
